Athersys (ATHX) Jumps After Being Granted FDA Orphan Drug Status
Athersys, Inc. (Nasdaq: ATHX) spikes on word it was granted FDA orphan drug stats for MPS-1 treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Energy Transfer Equity (ETE) Shares Fall 28%
- CAR-T Stocks See Strong Upside
- Sarepta Therapeutics (SRPT) PDUFA for Eteplirsen Extended
Create E-mail Alert Related CategoriesFDA, Momentum Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!